To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Summary
The bill would change the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to make it easier to develop novel medical therapies. It would affect drug and biotech companies, patients waiting for new cures, and the agencies that regulate them. The measure is intended to speed innovation and improve public health outcomes.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get real-time alerts when HR 10857 changes status, plus AI-powered summaries and stage predictions.
Sign up free